We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Involved in Scientific Research? Then you must have heard about MA-based Thermo Fisher Scientific, Inc. (TMO - Free Report) , one of the leading scientific instrument manufacturers across the world. Interestingly for this acquisition-friendly company, the latest buy out of Life Technologies is expected to give birth to an unrivaled market leader serving research, Specialty Diagnostics and applied markets.
Currently, Thermo Fisher has a Zacks Rank #3 (Hold) but that could change following its impressive second-quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at $2.00 per share. Thermo Fisher’s adjusted earnings per share of $2.03 beat this estimate by 1.5%.
Revenues: Thermo Fisher posted revenues of $4.535 billion, beating the Zacks Consensus Estimate for revenues of $4.496 billion.
Key Stats: Among its four business segments, Thermo Fisher delivered revenues of $1.28 billion (up 13%) in Life Sciences Solutions, $794 million (up 2%) in Analytical Instruments, $851 million (up 4%) in Specialty Diagnostics and $1.80 billion (up 6%) in Laboratory Products and Services respectively.
Major Factors: On account of unfavorable currency fluctuation, Thermo Fisher has lowered its 2016 revenue guidance. Management seemed upbeat about the company’s pending acquisition of FEI, which is expected to add leading capabilities in electron microscopy that complement Thermo Fisher’s analytical instruments portfolio
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Thermo Fisher earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher (TMO) Tops Q1 Earnings, Lowers '16 Sales View
Involved in Scientific Research? Then you must have heard about MA-based Thermo Fisher Scientific, Inc. (TMO - Free Report) , one of the leading scientific instrument manufacturers across the world. Interestingly for this acquisition-friendly company, the latest buy out of Life Technologies is expected to give birth to an unrivaled market leader serving research, Specialty Diagnostics and applied markets.
Currently, Thermo Fisher has a Zacks Rank #3 (Hold) but that could change following its impressive second-quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at $2.00 per share. Thermo Fisher’s adjusted earnings per share of $2.03 beat this estimate by 1.5%.
THERMO FISHER Price and EPS Surprise
THERMO FISHER Price and EPS Surprise | THERMO FISHER Quote
Revenues: Thermo Fisher posted revenues of $4.535 billion, beating the Zacks Consensus Estimate for revenues of $4.496 billion.
Key Stats: Among its four business segments, Thermo Fisher delivered revenues of $1.28 billion (up 13%) in Life Sciences Solutions, $794 million (up 2%) in Analytical Instruments, $851 million (up 4%) in Specialty Diagnostics and $1.80 billion (up 6%) in Laboratory Products and Services respectively.
Major Factors: On account of unfavorable currency fluctuation, Thermo Fisher has lowered its 2016 revenue guidance. Management seemed upbeat about the company’s pending acquisition of FEI, which is expected to add leading capabilities in electron microscopy that complement Thermo Fisher’s analytical instruments portfolio
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Thermo Fisher earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>